← All trials
NCT01053390
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2009
- Primary completion
- Dec 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 216
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Jiao Tong UniversityLead sponsor
- Capital Medical UniversityCollaborator
- Shengjing HospitalCollaborator
- Jilin UniversityCollaborator
- Eastern Hepatobiliary Surgery HospitalCollaborator
- Shandong Provincial HospitalCollaborator
- LanZhou UniversityCollaborator
- Shandong UniversityCollaborator
- China Medical UniversityCollaborator
- Second Military Medical UniversityCollaborator
- Peking UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Qinghai UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.